Generic Name
Liothyronine
Brand Names
Liomny, Cytomel
FDA approval date: May 08, 1956
Classification: l-Triiodothyronine
Form: Injection, Tablet
What is Liomny (Liothyronine)?
Liothyronine sodium injection is indicated in the treatment of myxedema coma/precoma. Liothyronine sodium injection can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Summary: This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimu...
PHASE II RANDOMIZED, INTERVENTION VERSUS NON- INTERVENTION, MULTI- CENTER STUDY OF THE EFFECTS OF THYROID HORMONE (T3) ON SAFETY/TOLERABILITY AND OXYGENATION IN SUBJECTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
Summary: It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).
Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine
Summary: Hypothyroidism is a thyroid disorder and one of the most common endocrine disorders. Hypothyroidism can have multiple causes; most patients suffer from primary autoimmune hypothyroidism (Hashimoto's disease), but also central hypothyroidism, hypothyroidism after total thyroidectomy due to thyroid carcinoma, or hypothyroidism due to therapy of Graves' disease occur. Most patients with hypothyroidis...
Related Latest Advances
Brand Information
Liomny (Liothyronine Sodium)
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
- Thyroid hormones, including LIOMNY, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.
- In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.
- Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects
1DOSAGE FORMS AND STRENGTHS
Tablets (white to off-white, round, SC) available as follows:
- 5 mcg: debossed “σ” on one side and “5 μg” on the other side
- 25 mcg: debossed “σ” on one side and BISECTED on the other side with “25” debossed above the bisect and on “μg” debossed below the bisect
- 50 mcg: debossed “σ” on one side and BISECTED on the other side with “50” debossed above the bisect and on “μg” debossed below the bisect
2CONTRAINDICATIONS
LIOMNY is contraindicated in patients with uncorrected adrenal insufficiency
3ADVERSE REACTIONS
Adverse reactions associated with LIOMNY therapy are primarily those of hyperthyroidism due to therapeutic overdosage
General:fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
Central nervous system:headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
Musculoskeletal: tremors, muscle weakness and cramps
Cardiovascular:palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
Respiratory:dyspnea
Gastrointestinal:diarrhea, vomiting, abdominal cramps, elevations in liver function tests
Dermatologic:hair loss, flushing
Endocrine:decreased bone mineral density
Reproductive:menstrual irregularities, impaired fertility
Adverse Reactions in Pediatric Patients
Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving thyroid replacement therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in pediatric patients with resultant compromised adult height.
Hypersensitivity Reactions
Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing.
To report SUSPECTED ADVERSE REACTIONS, contact Sigmapharm Laboratories, LLC, Pharmacovigilance at 1-855-332-0731 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Central nervous system:headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
Musculoskeletal: tremors, muscle weakness and cramps
Cardiovascular:palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
Respiratory:dyspnea
Gastrointestinal:diarrhea, vomiting, abdominal cramps, elevations in liver function tests
Dermatologic:hair loss, flushing
Endocrine:decreased bone mineral density
Reproductive:menstrual irregularities, impaired fertility
Adverse Reactions in Pediatric Patients
Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving thyroid replacement therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in pediatric patients with resultant compromised adult height.
Hypersensitivity Reactions
Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing.
To report SUSPECTED ADVERSE REACTIONS, contact Sigmapharm Laboratories, LLC, Pharmacovigilance at 1-855-332-0731 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
4OVERDOSAGE
The signs and symptoms of overdosage are those of hyperthyroidism
Reduce the LIOMNY dose or temporarily discontinued if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient's medical status.
For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.
5DESCRIPTION
LIOMNY contains the active ingredient, liothyronine (L-triiodothyronine or LT3), a synthetic form of a thyroid hormone liothyronine in sodium salt form. It is chemically designated as L-Tyrosine,
LIOMNY contains liothyronine sodium equivalent to liothyronine in 5 mcg, 25 mcg, and 50 mcg. Inactive ingredients consist of calcium sulfate dihydrate, corn starch, gelatin, magnesium stearate and mannitol.
6HOW SUPPLIED/STORAGE AND HANDLING
LIOMNY tablets (white to off-white, round, SC) are supplied as follows:
7LIOMNY TMMCG- 30 TABLETS CONTAINER LABEL
Principal Display Panel – 5 mcg Bottle Label
NDC 42794-
LIOMNY
(liothyronine sodium tablets, USP)
5 mcg*
PHARMACIST: SEE SIDE PANEL FOR
WARNINGS.
WARNINGS.
Sigmapharm Laboratories, LLC
Rx only
30 Tablets
8LIOMNY TMMCG- 30 TABLETS CONTAINER LABEL
Principal Display Panel – 25 mcg Bottle Label
NDC 42794-
LIOMNY
(liothyronine sodium tablets, USP)
25 mcg*
PHARMACIST: SEE SIDE PANEL FOR
WARNINGS.
WARNINGS.
Sigmapharm Laboratories, LLC
Rx only
30 Tablets
9LIOMNY TMMCG- 30 TABLETS CONTAINER LABEL
Principal Display Panel – 50 mcg Bottle Label
NDC 42794-
LIOMNY
(liothyronine sodium tablets, USP)
50 mcg*
PHARMACIST: SEE SIDE PANEL FOR
WARNINGS.
WARNINGS.
Sigmapharm Laboratories, LLC
Rx only
30 Tablets